Published On: Wed, Oct 19th, 2016

Masimo Corporation (NASDAQ:MASI) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Masimo Corporation (NASDAQ:MASI).

Most recent broker ratings

08/04/2016 – Masimo Corporation had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 63 price target on the stock.

08/04/2016 – Masimo Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 55 price target on the stock.

05/05/2016 – Masimo Corporation had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 50 price target on the stock.

01/06/2016 – Masimo Corporation was downgraded to “outperform” by analysts at Raymond James. They now have a USD 46 price target on the stock.

08/05/2015 – Masimo Corporation had its “hold” rating reiterated by analysts at BTIG Research.

05/08/2015 – Masimo Corporation was upgraded to “buy” by analysts at Zacks. They now have a USD 39 price target on the stock.

01/09/2015 – Masimo Corporation had its “sell” rating reiterated by analysts at Off Wall Street.

08/11/2014 – Masimo Corporation had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 27 price target on the stock.

08/08/2014 – Masimo Corporation had its “market perform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 24 price target on the stock.

10/31/2013 – Masimo Corporation had its “hold” rating reiterated by analysts at Feltl & Co.. They now have a USD 26 price target on the stock.

The share price of Masimo Corporation (NASDAQ:MASI) was up +0.32% during the last day of trading, with a day high of 59.70. 280142 shares were traded during the last session.

The stock’s 50 day moving average is 59.20 and its 200 day moving average is 52.48. The stock’s market capitalization is 2.92B. Masimo Corporation has a 52-week low of 33.03 and a 52-week high of 60.81.

Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. The Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC)-based viewing station or by care providers through their voice-over-Internet Protocol (IP) phones.